Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $251,380. The enterprise value is $1.93 million.
| Market Cap | 251,380 |
| Enterprise Value | 1.93M |
Important Dates
The last earnings date was Monday, August 24, 2026, before market open.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 570,022 shares outstanding. The number of shares has increased by 303.74% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 570,022 |
| Shares Change (YoY) | +303.74% |
| Shares Change (QoQ) | +198.64% |
| Owned by Insiders (%) | 14.26% |
| Owned by Institutions (%) | 3.44% |
| Float | 488,726 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.08 |
| Forward PS | n/a |
| PB Ratio | 0.02 |
| P/TBV Ratio | 0.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.23 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.10% and return on invested capital (ROIC) is -63.83%.
| Return on Equity (ROE) | -26.10% |
| Return on Assets (ROA) | -38.74% |
| Return on Invested Capital (ROIC) | -63.83% |
| Return on Capital Employed (ROCE) | -61.66% |
| Weighted Average Cost of Capital (WACC) | 1.15% |
| Revenue Per Employee | $68,156 |
| Profits Per Employee | -$54,578 |
| Employee Count | 45 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.20% in the last 52 weeks. The beta is 2.26, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 2.26 |
| 52-Week Price Change | -96.20% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 4.26 |
| Relative Strength Index (RSI) | 22.30 |
| Average Volume (20 Days) | 3,443,821 |
Short Selling Information
The latest short interest is 179,643, so 13.53% of the outstanding shares have been sold short.
| Short Interest | 179,643 |
| Short Previous Month | 19,900 |
| Short % of Shares Out | 13.53% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, SCNI had revenue of $3.07 million and -$2.46 million in losses. Loss per share was -$4.62.
| Revenue | 3.07M |
| Gross Profit | -3.71M |
| Operating Income | -8.47M |
| Pretax Income | -2.46M |
| Net Income | -2.46M |
| EBITDA | -6.55M |
| EBIT | -8.47M |
| Loss Per Share | -$4.62 |
Balance Sheet
The company has $1.71 million in cash and $3.39 million in debt, with a net cash position of -$1.68 million or -$2.95 per share.
| Cash & Cash Equivalents | 1.71M |
| Total Debt | 3.39M |
| Net Cash | -1.68M |
| Net Cash Per Share | -$2.95 |
| Equity (Book Value) | 10.71M |
| Book Value Per Share | 21.15 |
| Working Capital | 443,000 |
Cash Flow
In the last 12 months, operating cash flow was -$7.38 million and capital expenditures -$127,000, giving a free cash flow of -$7.50 million.
| Operating Cash Flow | -7.38M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 1.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -7.50M |
| FCF Per Share | -$13.16 |
Margins
Gross margin is -121.10%, with operating and profit margins of -276.10% and -80.08%.
| Gross Margin | -121.10% |
| Operating Margin | -276.10% |
| Pretax Margin | -80.08% |
| Profit Margin | -80.08% |
| EBITDA Margin | -213.50% |
| EBIT Margin | -276.10% |
| FCF Margin | n/a |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -303.74% |
| Shareholder Yield | -303.74% |
| Earnings Yield | -1,047.38% |
| FCF Yield | -2,984.72% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 118.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 21, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |